Condition
Anti-PD-1
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Recruiting2
Unknown1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT05125055Phase 2Recruiting
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
NCT05069857Phase 2Recruiting
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
NCT05998122Phase 2Not Yet Recruiting
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
NCT04815408Phase 2Unknown
PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer
Showing all 4 trials